arrow
C

Corinne Vandermeulen

n gsk, wavre, belgiumcontributionconceptualization, data curation, formal analysis, writing – review & editing
H指数:30
被引数:3,285

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50–59 years of age, including at-increased-risk adults: A randomized controlled trial

AS01E佐剂呼吸道合胞病毒前融合F蛋白疫苗在50~59岁成人(包括高风险成人)中的免疫持久性与安全性:一项随机对照试验

2025-11-050
OAAI
Dosimetry and kinetic modelling of [18F]JNJ-64511070, a novel PET ligand to quantify AMPA-associated TARP-γ8 receptors in the human brain

剂量测定和动力学建模研究 [18F]JNJ-64511070,一种用于定量人脑中AMPA相关TARP-γ8受体的新型PET配体

2025-07-220
PRE
Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies

9价人乳头瘤病毒疫苗的免疫原性: 来自五项3期研究的事后分析

2025-01-220
OA
Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age

呼吸道合胞病毒融合前F蛋白疫苗在50-59岁成年人中的免疫原性和一致性安全性与 ≥ 60岁相比

2024-08-054
OAAI
Respiratory Syncytial Virus Disease Burden in Community-Dwelling and Long-Term Care Facility Older Adults in Europe and the United States: A Prospective Study
2023-03-0112
OAAI
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

呼吸道合胞病毒Prefusion F (RSVPreF3) 候选疫苗在老年人中的安全性和免疫原性: 1/2期随机临床试验

2022-07-2970
OAAI
Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV)

9价人乳头瘤病毒疫苗在实体器官移植受者和感染人类免疫缺陷病毒 (HIV) 的成年人中的免疫原性和安全性

2020-12-2928
OAAI
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers
2019-04-0113
OAAI